G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. AMZN
2. INTC
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SNDK
8. FND
9. RIVN
10. SBUX

Go back to G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c

G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

August 3, 2022 6:30 AM EDT

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue -

- Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Colorectal Cancer (mCRC) (PRESERVE 1) -

- Completed Patient Enrollment in Phase 2 Mechanism of Action Trial of Trilaciclib in Neoadjuvant Triple Negative Breast Cancer (TNBC) -

- Achieved Target Enrollment in Phase 2 Trial of Trilaciclib in Bladder Cancer (mUC) (PRESERVE 3) -

- Announced Approval of COSELA (trilaciclib hydrochloride for... More